Pharmaceutical

SAR-442970 by Sanofi for Hidradenitis Suppurativa: Likelihood of Approval

SAR-442970 is under clinical development by Sanofi and currently in Phase II for Hidradenitis Suppurativa.

Feb 20, 2024 - 18:00
SAR-442970 is under clinical development by Sanofi and currently in Phase II for Hidradenitis Suppurativa.
Read the original article

Tags:

Previous Article

Ketamine by NRX Pharmaceuticals for Bipolar Disorder (Manic Depression): Likelih...

Next Article

Not Disclosed Neurodegeneration by Eli Lilly and Co for Neurodegenerative Diseas...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Santhera and Catalyst to market DMD drug vamorolone in North America

Santhera and Catalyst to market DMD drug vamorolone in ...

Jul 19, 2023

Maxion scoops £2m UK grant to develop autoimmune disease treatment

Maxion scoops £2m UK grant to develop autoimmune diseas...

Apr 20, 2023

Ebola vaccine cuts fatality even in people who were infected before the jab, new study shows

Ebola vaccine cuts fatality even in people who were inf...

Feb 13, 2024